A Comparative Study of Levofloxacin and Ceftriaxone in the Treatment of Hospitalized Patients with Pneumonia
| Autor: | S R Norrby, P A Willcox, W Petermann, N Vetter, E Salewski |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male Microbiology (medical) Ofloxacin medicine.medical_specialty Adolescent International Cooperation Population Levofloxacin Gram-Positive Bacteria law.invention Anti-Infective Agents Randomized controlled trial law Internal medicine Gram-Negative Bacteria Pneumonia Bacterial medicine Clinical endpoint Humans education Aged Antibacterial agent Aged 80 and over education.field_of_study General Immunology and Microbiology business.industry Ceftriaxone General Medicine Middle Aged medicine.disease Cephalosporins Surgery Community-Acquired Infections Hospitalization Pneumonia Treatment Outcome Infectious Diseases Female business medicine.drug |
| Zdroj: | Scandinavian Journal of Infectious Diseases. 30:397-404 |
| ISSN: | 1651-1980 0036-5548 |
| DOI: | 10.1080/00365549850160710 |
| Popis: | A multinational, multicentre, open, randomised study in hospitalised patients with pneumonia compared levofloxacin 500 mg twice daily with ceftriaxone 4 g i.v. once daily. Levofloxacin patients started on i.v. treatment and switched to oral on d 3-5 of therapy if signs and symptoms had improved. The minimum treatment duration was 5 d, except for treatment failure, and the median 8 d. The primary efficacy analysis was based on the per-protocol assessment of the clinical cure rate determined 2-5 d after the end of treatment in the per-protocol (PP) population (levofloxacin 127, ceftriaxone 139). Of 625 patients enrolled and randomized, 6 received no treatment, giving an intention-to-treat (ITT) population of 619 (levofloxacin 314, ceftriaxone 305). At the clinical endpoint, 2-5 d after the end of treatment, the cure rates for levofloxacin and ceftriaxone were similar in both the ITT (76% and 75%, respectively) and PP (87% and 86%, respectively) populations. Both drugs were well tolerated. Twice-daily levofloxacin 500 mg, either i.v. or as sequential i.v./oral therapy, was as effective as i.v. once-daily ceftriaxone 4 g in the treatment of hospitalized patients with pneumonia and offers the advantage of sequential therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|